Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 10/20 | 0.62 |
| ▸ | CYP11B1 | P15538 | 9/20 | 0.59 |
| ▸ | CYP11B2 | P19099 | 9/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | QPCT | Q16769 | 1/20 | 0.53 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.53 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.53 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3457021 | 1.00 | CYP19A1 (0.62) | CYP19A1CYP11B1CYP11B2ADRA2CTBXAS1 | |
| SCHEMBL773136 | 0.83 | CYP11B1 (0.59) | CYP19A1CYP11B1CYP11B2TBXAS1CYP1A2 | |
| SCHEMBL773135 | 0.83 | CYP11B1 (0.59) | CYP19A1CYP11B1CYP11B2TBXAS1CYP1A2 | |
| SCHEMBL9853963 | 0.79 | CYP19A1 (0.80) | CYP19A1CYP11B1CYP11B2ADRA2CTBXAS1 | |
| SCHEMBL394308 | 0.79 | CYP11B1 (0.83) | CYP19A1CYP11B1CYP11B2ADRA2CTBXAS1 | |
| SCHEMBL5478998 | 0.78 | CYP19A1 (0.73) | CYP19A1CYP11B1CYP11B2ADRA2CTBXAS1 | |
| SCHEMBL1703627 | 0.76 | CYP19A1 (0.50) | CYP19A1CYP11B1CYP11B2TBXAS1CYP1A2 | |
| SCHEMBL24247782 | 0.76 | CYP19A1 (0.70) | CYP19A1CYP11B1CYP11B2ADRA2CTBXAS1 | |
| SCHEMBL3754518 | 0.76 | HDAC1 (0.64) | CYP19A1 | |
| SCHEMBL3460275 | 0.76 | HDAC1 (0.64) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250165-B1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2018-07-25 | — | — | EP | disclosed |
| US-8202856-B2 | Triazole oxadiazoles derivatives | MERCK SERONO SA (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305092-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | OXA1L, RO60, PDCD11 | CYP19A1 1163/4885CYP11B1 425/4885CYP11B2 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.